Related Experiment Video

Updated: May 24, 2025

Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
08:07

Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line

Published on: February 17, 2016

71.3K

Lack of efficacy of sofosbuvir in Human Pegivirus associated neurological disorders

V Pourcher1, M Boudot de La Motte2, M Touat3

  • 1Infectious Diseases Department, Pierre-Louis Institute of Epidemiology and Public Health (iPLESP), Inserm U1136, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Revue Neurologique
|February 28, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
09:07

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses

Published on: June 14, 2020

10.6K
A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain
07:52

A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain

Published on: April 9, 2019

8.6K

Related Experiment Videos

Last Updated: May 24, 2025

Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
08:07

Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line

Published on: February 17, 2016

71.3K
Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
09:07

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses

Published on: June 14, 2020

10.6K
A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain
07:52

A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain

Published on: April 9, 2019

8.6K

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
140
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209

Articles linked to this work by shared authors, journal, and citation graph.

Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.

Revue neurologique·2024

Prognosis of glioblastoma patients improves significantly over time interrogating historical controls.

European journal of cancer (Oxford, England : 1990)·2024

Epileptic seizures in patients with primary central nervous system lymphoma: A systematic review.

Revue neurologique·2023

Recent advances in the diagnosis and the treatment of primary CNS lymphoma.

Revue neurologique·2023

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.

Annals of hematology·2023

Molecular and clinical diversity in primary central nervous system lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

The good, the bad, and the ugly: A three-circuit model of Parkinson's tremor.

Revue neurologique·2026

The eyes and Parkinsonian syndromes.

Revue neurologique·2026

Autosomal recessive cerebellar ataxia: What have we learnt in the last 30 years?

Revue neurologique·2026

Trends and regional disparities in triptan dispensing in France between 2014 and 2025: A nationwide open-data study.

Revue neurologique·2026

Access to hospital-based rehabilitation for people with multiple sclerosis in France: A nationwide study (2017-2023).

Revue neurologique·2026

Effect of levodopa-carbidopa intestinal gel infusion on objective measures of daytime sleepiness and nocturnal sleep in Parkinson's disease.

Revue neurologique·2026

Clinical Practice of Single-Molecule Real-Time Sequencing in the Diagnosis of Spinal Muscular Atrophy.

Molecular genetics & genomic medicine·2026

Astrocytic cathepsin D promotes α-synuclein processing and Lewy neurite-like aggregate maturation.

EMBO reports·2026

Long-term clinical and biomarker observations following rituximab exposure in two siblings with CSF1R-related leukoencephalopathy: a preliminary familial case series.

Communications medicine·2026

What can narcolepsy teach us about hypocretin and dementia?

Ageing research reviews·2026

Estradiol Attenuates Cardiac Apoptosis and Modulates Cardiovascular Remodeling in Ovariectomized Female Rats with 6-Hydroxydopamine-Induced Parkinsonism.

Physiology & behavior·2026

From patient cells to patient therapy: Twenty years of iPSC-based translation in neurodegenerative disease.

Cell reports. Medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us